Skip to main content
Sonnet BioTherapeutics Holdings, Inc. (SONN)
NASDAQ: SONN · Real-Time Price · USD
3.950
+0.960 (32.11%)
At close: Aug 13, 2025, 4:00 PM
3.480
-0.470 (-11.90%)
Pre-market: Aug 14, 2025, 9:20 AM EDT

SONN Revenue

Sonnet BioTherapeutics Holdings had revenue of $1.00M in the twelve months ending March 31, 2025, up 978.39% year-over-year. In the fiscal year ending September 30, 2024, Sonnet BioTherapeutics Holdings had annual revenue of $18.63K, down -87.40%.

Revenue (ttm)
$1.00M
Revenue Growth
+978.39%
P/S Ratio
10.69
Revenue / Employee
$76,923
Employees
13
Market Cap
24.74M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Sep 30, 202418.63K-129.18K-87.40%
Sep 30, 2023147.81K-202.14K-57.76%
Sep 30, 2022349.94K-133.68K-27.64%
Sep 30, 2021483.63K--
Sep 30, 2020---
Sep 30, 2019 Pro Pro Pro
Sep 30, 2018 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 422.82B
Johnson & Johnson 90.63B
Merck & Co. 63.62B
AbbVie 58.33B
AstraZeneca 56.50B
Novartis AG 55.19B
Eli Lilly and Company 53.26B
Novo Nordisk 49.11B
Revenue Rankings

SONN News

More News